SUVEN PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 648.3 INR | +2.01% |
|
+5.02% | -10.31% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 49.3 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -10.31% | 1.98B | D- | ||
| +45.82% | 765B | C+ | ||
| -6.16% | 354B | C+ | ||
| +19.86% | 331B | B- | ||
| +9.32% | 299B | C+ | ||
| +18.45% | 248B | B+ | ||
| -0.78% | 219B | A+ | ||
| +11.88% | 216B | B- | ||
| +5.90% | 164B | C+ | ||
| -0.73% | 162B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SUVENPHAR Stock
- Ratings Suven Pharmaceuticals Limited
